Výsledky vyhledávání - "Dan Byczkowski"

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Autor: Stephen B. Hanauer, Paul F. Pollack, Ju Li, Remo Panaccione, William J. Sandborn, Robert Enns, Paul Rutgeerts, Stefan Schreiber, Dan Byczkowski, Jean-Frederic Colombel, J. D. Kent

Publikováno v: Gastroenterology. 132(1)

Background & Aims: This study evaluated the efficacy and safety of adalimumab, a fully human, anti‐tumor necrosis factor monoclonal antibody administered subcutaneously, in the maintenance of response and remission in patients with moderate to seve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc321ce8976ab2a3baaf8c5e06889c8e
https://pubmed.ncbi.nlm.nih.gov/18223389

Zobrazit plný text záznamu

Akademický článek

Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.

Autor: Schmitt, Christophe, Portron, Agnès, Jadidi, Shirin, Sarkar, Neena, DiMarchi, Richard

Publikováno v: Diabetes, Obesity & Metabolism; Oct2017, Vol. 19 Issue 10, p1436-1445, 10p

Zobrazit plný text záznamu

Akademický článek

Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.

Autor: Portron, Agnès, Jadidi, Shirin, Sarkar, Neena, DiMarchi, Richard, Schmitt, Christophe

Publikováno v: Diabetes, Obesity & Metabolism; Oct2017, Vol. 19 Issue 10, p1446-1453, 8p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání